In brief: Ipsen closes Clementia acquisition

Pfizer completes acquisition of Swiss biotech Therachon

Ipsen has closed its acquisition of Canada’s Clementia Pharmaceuticals after securing approval from shareholders and the Quebec Superior Court.

Clementia shareholders will receive $25.00 per share in cash up front and one contingent value right (CPV) per share entitling them to receive $6.00 per CVR upon the US FDA acceptance of the regulatory filing for palovarotene for the treatment of multiple osteochondromas.

Clarissa Desjardins, Clementia CEO, said: “Going forward, we are confident that Ipsen, with its shared patient-centric culture, proven development capabilities and global commercial footprint, will fulfil our ambition of delivering palovarotene to patients worldwide as quickly as possible.”